Compare Baxter International Inc (BAX) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Manhattan Associates Inc — how do they compare? Baxter International Inc trades at $27.04 (market cap $14.27B), while Manhattan Associates Inc trades at $191.86 (market cap $11.38B). The key difference: Baxter International Inc is the larger of the two by market cap, and Baxter International Inc pays a 0.14% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| BAX | MANH | |
|---|---|---|
Market Cap | $14.27B | $11.38B |
Sector | Health | Technology |
52-Week High | $28.35 | $220.19 |
52-Week Low | $15.80 | $120.88 |
Enterprise Value | $21.79B | $11.25B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
MANH trades at $189.98, down 2.92% on the day, but maintains a bullish technical outlook with strong moving average signals and a golden cross formation. The company reported Q2 2026 EPS of $1.39, beating estimates, with cloud revenue growth driving performance. However, high valuation ratios like a P/E of 55.93 and P/B of 72.26 suggest premium pricing. Recent news highlights an ongoing legal investigation into fiduciary duties by Rosen Law Firm, adding a layer of scrutiny.
The stock's upside is supported by analyst consensus with a $210.33 price target and 80% buy ratings, but risks include elevated valuations, potential legal overhangs, and projected net cash flow turning negative in 2026. Investors should weigh robust profitability metrics against these headwinds for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
